X4 Pharmaceuticals, Inc. $XFOR Shares Acquired by Kingdon Capital Management L.L.C.

Kingdon Capital Management L.L.C. increased its holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 300.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 933,332 shares of the company’s stock after purchasing an additional 700,000 shares during the period. Kingdon Capital Management L.L.C. owned 1.07% of X4 Pharmaceuticals worth $3,192,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. Rosalind Advisors Inc. acquired a new stake in X4 Pharmaceuticals in the 3rd quarter worth about $5,283,000. Deep Track Capital LP purchased a new position in shares of X4 Pharmaceuticals during the 3rd quarter worth about $3,839,000. Boothbay Fund Management LLC purchased a new position in shares of X4 Pharmaceuticals during the 3rd quarter worth about $1,176,000. Vanguard Group Inc. boosted its position in shares of X4 Pharmaceuticals by 77.0% in the third quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock worth $1,404,000 after acquiring an additional 178,593 shares during the last quarter. Finally, Palumbo Wealth Management LLC purchased a new stake in X4 Pharmaceuticals in the third quarter valued at approximately $326,000. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research note on Monday, December 29th. Guggenheim began coverage on X4 Pharmaceuticals in a report on Monday, March 9th. They set a “buy” rating and a $12.00 price objective for the company. Zacks Research cut X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 26th. Wall Street Zen downgraded X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, November 30th. Finally, Stifel Nicolaus set a $10.00 price objective on X4 Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, December 5th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $28.88.

X4 Pharmaceuticals Trading Down 4.9%

NASDAQ XFOR opened at $3.69 on Monday. The stock has a market cap of $322.65 million, a P/E ratio of -0.36 and a beta of 0.43. The company’s fifty day simple moving average is $3.66 and its 200-day simple moving average is $3.61. The company has a current ratio of 5.65, a quick ratio of 5.48 and a debt-to-equity ratio of 1.23. X4 Pharmaceuticals, Inc. has a 52 week low of $1.35 and a 52 week high of $10.49.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.